公开(公告)号：EP2330896A4

公开(公告)日：2012-11-28

申请号：EP09812773

申请日：2009-09-06

申请人： UNIV BEN GURION ,  MOR RESEARCH APPLIC LTD

发明人： NATHAN ILANA ,  LEWIS ELI ,  KHALFIN BORIS

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K38/57

CPC分类号： A61K38/57 ,  A61K31/70 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP1458741B1

公开(公告)日：2012-10-17

申请号：EP03716126.2

申请日：2003-02-20

申请人： SIRNA THERAPEUTICS, INC.

发明人： McSWIGGEN, James ,  BEIGELMAN, Leonid ,  MACEJAK, Dennis ,  ZINNEN, Shawn ,  PAVCO, Pamela ,  MORRISSEY, David ,  FOSNAUGH, Kathy ,  MOKLER, Victor ,  JAMISON, Sharon

IPC分类号： C12N15/11 ,  C12P19/34 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  A01N43/04 ,  A61K31/713

CPC分类号： C12N15/8218 ,  A61K38/00 ,  A61K47/54 ,  C07H21/02 ,  C12N15/111 ,  C12N15/1131 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/318 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/332 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2310/53 ,  C12N2320/51 ,  C12N2330/30 ,  Y02A50/393 ,  C12N2310/3521

摘要： The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

公开(公告)号：EP2506711A1

公开(公告)日：2012-10-10

申请号：EP10834963.0

申请日：2010-11-23

申请人： OPKO Health, Inc.

发明人： AHMED, Tahir

IPC分类号： A01N43/04 ,  A61K31/715

CPC分类号： A61K31/7016 ,  A61K9/0053 ,  A61K47/32

摘要： Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.

摘要翻译： 公开了用于哮喘或哮喘相关疾病的超硫酸化二糖。 化合物与增强超硫酸化二糖的口服递送的试剂一起配制。 递送剂选自具有离子侧链的天然或合成聚合物以及相对于没有这种试剂递送药物而言改善二糖的生物利用度的其他化合物或类型的化合物。 超硫酸化二糖由肝素或其盐制成。

公开(公告)号：EP2490530A1

公开(公告)日：2012-08-29

申请号：EP10825785.8

申请日：2010-10-22

申请人： The Washington University

发明人： JANETKA, James, W. ,  HAN, Zhenfu ,  HULTGREN, Scott ,  PINKNER, Jerry ,  CUSUMANO, Corrine

IPC分类号： A01N43/04 ,  A61K31/70

CPC分类号： A61K31/70 ,  C07H15/18 ,  C07H15/20 ,  C07H15/203 ,  C07H15/26 ,  C07H17/00 ,  C07H17/04 ,  C07H17/075 ,  Y02A50/473

摘要： The present invention encompasses compounds and methods for treating urinary tract infections.

公开(公告)号：EP2375896A4

公开(公告)日：2012-07-18

申请号：EP09828194

申请日：2009-11-19

申请人： GLAXOSMITHKLINE LLC

发明人： MARTIN MICHAEL TOLAR ,  MCCLURE MICHAEL S ,  ELITZIN VASSIL

IPC分类号： C07D231/20 ,  A01N43/04 ,  C07H17/02

CPC分类号： C07D231/20 ,  C07H17/02

公开(公告)号：EP2473042A1

公开(公告)日：2012-07-11

申请号：EP10814536.8

申请日：2010-09-02

申请人： Synedgen, Inc. ,  Baker, Shena D. ,  Wiesmann, William P. ,  Townsend, Stacy

发明人： BAKER, Shenda ,  WIESMANN, William, P. ,  TOWNSEND, Stacy

IPC分类号： A01N43/04

CPC分类号： A61K31/722 ,  A61K9/0014 ,  A61K9/0043 ,  A61K9/0053 ,  Y02A50/473 ,  Y02A50/475

摘要： Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or deritvatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.

公开(公告)号：EP2473040A1

公开(公告)日：2012-07-11

申请号：EP10800596.8

申请日：2010-07-16

申请人： Pacific Arrow Limited

发明人： CHAN, Pui-Kwong ,  MAK, May Sung

IPC分类号： A01N43/04

CPC分类号： A61K31/704 ,  A61K31/7042 ,  C07J63/008

摘要： This invention provides compounds, compositions, extracts, and their methods and uses for inhibiting the cancer invasion, cells invasion, cancer cell invasion,and cancer metastasis, wherein the cells comprise cancer cells, wherein the cancers comprise breast cancer, leukocytic cancer, liver cancer, ovarian cancer, bladder cancer, prostatic cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphhatic cancer, pancreatic cancer, stomach cancer and thyroid cancer.

公开(公告)号：EP2254412A4

公开(公告)日：2012-05-09

申请号：EP08731883

申请日：2008-03-11

申请人： ELIXIR MEDICAL CORP

发明人： YAN JOHN ,  ZHENG XIAOXIA ,  BHAT VINAYAK D

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61P27/02

CPC分类号： A61K31/70 ,  A61K31/436

公开(公告)号：EP2299815A4

公开(公告)日：2012-04-18

申请号：EP09758700

申请日：2009-05-28

申请人： GALDERMA SA

发明人： PARKS DEAN L ,  PARKS JEFFREY D

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61P17/02 ,  A61P43/00

CPC分类号： A61K31/351 ,  A61K9/0014 ,  A61K31/7048

公开(公告)号：EP1876893B1

公开(公告)日：2012-04-11

申请号：EP06750227.8

申请日：2006-04-14

申请人： GERON CORPORATION ,  MEMORIAL SLOAN-KETTERING CANCER CENTER

发明人： MOORE, Malcolm, A., S. ,  CHIN, Allison, C.

IPC分类号： C12N15/113 ,  A61K31/454 ,  A01N43/04 ,  A01N61/00

CPC分类号： C12N15/1137 ,  A61K31/454 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/3145 ,  C12N2310/3515 ,  C12Y207/07049 ,  A61K2300/00

摘要： A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.